# A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

> **NCT02452918** · PHASE4 · COMPLETED · sponsor: **The Medicines Company** · enrollment: 17 (actual)

## Conditions studied

- Acute Bacterial Skin and Skin Structure Infection

## Interventions

- **DRUG:** Oritavancin
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT02452918
- **Lead sponsor:** The Medicines Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-29
- **Primary completion:** 2016-07-05
- **Final completion:** 2016-07-05
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2023-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02452918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02452918, "A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02452918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*